시장보고서

상품코드

1654161

급성 반복 발작 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별, 부문 예측(2025-2030년)

Acute Repetitive Seizures Market Size, Share & Trends Analysis Report By Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) And Segment Forecasts, 2025 - 2030

발행일: 2025년 01월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

급성 반복 발작 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 급성 반복 발작 시장 규모는 2030년까지 64억 8,000만 달러에 달할 것으로 예상되며, 2025년부터 2030년까지 12.7%의 연평균 성장률로 확대될 것으로 전망됩니다.

뇌전증에 대한 인식을 높이기 위한 노력의 증가가 시장을 이끄는 주요 요인입니다.

현재 시장은 주로 경구용 벤조디아제핀(디아제팜 및 로라제팜)을 포함하는 제네릭 의약품이 주도하고 있습니다. 직장용 디아제팜은 미국에서, 구강용 미다졸람은 유럽 연합에서 유일하게 승인된 약물입니다. 그 외 디아제팜(경구 및 근육 내), 미다졸람(협측, 비강 내, 근육 내), 로라제팜(경구, 비강 내, 설하), 프로게스테론 등의 약물은 주로 오프라벨로 사용되고 있습니다. 이 시장은 소수의 주요 기업과 높은 시장 점유율로 통합될 것으로 예상됩니다.

또한 각국 정부는 의료비 지출을 억제하기 위해 클리닉 및 재택 의료와 같은 외래 진료 모델을 통해 병원 입원 및 현장 치료 비용을 줄이기 위한 노력을 지속하고 있습니다. 인도와 중국과 같은 신흥 경제국에서는 이러한 의료 개혁을 점점 더 많이 시행하고 있으며, 이는 급성 반복 발작 시장의 성장을 촉진할 것으로 예상됩니다.

약물 투여 경로에는 여러 가지가 있으며, 그 중 비강 경로가 구강, 직장, 비경구 등 다른 경로보다 가장 선호됩니다. 구강 경로는 병원 밖에서도 약물을 투여할 수 있기 때문에 소아 발작을 앓고 있는 어린이의 간병인과 부모가 선호합니다.

급성 반복 발작 시장 보고서 하이라이트

세계의 급성 반복 발작 시장 규모는 2024년에 31억 5천만 달러로 추정되었으며 예측 기간 동안 12.7%의 CAGR을 기록 할 것으로 예상됩니다.
USL-261은 신속한 발작 제어를 목표로하는 비강 내 치료제로서의 효과로 인해 시장을 장악하고 2024년에 44.5%의 점유율을 차지했습니다.
북미의 급성 반복 발작 시장은 2024년 43.0%의 매출 점유율로 글로벌 시장을 지배했습니다. 이 지역의 시장 성장은 뇌전증 및 신경 장애의 높은 유병률과 강력한 의료 인프라에 의해 주도되고 있습니다.
일본의 급성 반복 발작 시장은 2024년 아시아태평양 급성 반복 발작 시장을 지배할 것으로 예상됩니다. 인구 고령화와 함께 신경계 질환에 대한 인식이 높아지면서 효과적인 치료법에 대한 수요가 증가하고 있습니다.

지역별 시장 점유율 분석(2024년, 2030년)
지역별 시장 대시보드
시장 규모, 예측 동향 분석(2018-2030년)
북미
- 국가별(2018-2030년)
- 미국
- 캐나다
- 멕시코
유럽
- 국가별(2018-2030년)
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 덴마크
- 스웨덴
아시아태평양
- 국가별(2018-2030년)
- 일본
- 중국
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 국가별(2018-2030년)
- 브라질
- 아르헨티나
중동 및 아프리카
- 국가별(2018-2030년)
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제6장 경쟁 구도

참가자 개요
기업의 시장 포지셔닝 분석
기업 분류
전략 매핑
기업 프로파일, 상장 기업
- UCB SA, Belgium
- Neurelis, Inc.
- Bausch Health Companies Inc.
- Grupo Ferrer Internacional, SA
- SERB

HBR 25.03.10

Acute Repetitive Seizures Market Growth & Trends:

The global acute repetitive seizures market size is estimated to reach USD 6.48 billion by 2030, expanding at a CAGR of 12.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rise in the number of initiatives to increase awareness about epilepsy is the major factor driving the market.

The market is currently led by generic drugs which mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only approved drug for use in U.S. and buccal midazolam in the European Union. Other drugs, such as diazepam (oral and intramuscular), midazolam (buccal, intranasal, intramuscular), lorazepam (oral, intranasal, sublingual), and progesterone are majorly used off label. The market is expected to be consolidated with a few major companies and a high market share.

Furthermore, in an attempt to curb healthcare expenditure, governments are making continuous efforts to reduce hospital stays and on-site treatment costs via outpatient care models, such as clinic and home healthcare. Emerging economies like India and China, are increasingly implementing such healthcare reform, which is expected to propel the growth of acute repetitive seizures market.

There are several routes of drug administration; out of which, the nasal route is the most preferred over others, such as buccal, rectal, and parenteral. The buccal route is preferred by caregivers and parents for children suffering from pediatric seizures since medication can be administered even outside the hospital.

Acute Repetitive Seizures Market Report Highlights:

Global acute repetitive seizures market size was estimated at USD 3.15 billion in 2024 and is expected to register a CAGR of 12.7% over the forecast period
USL-261 dominated the market and accounted for a share of 44.5% in 2024, owing to its effectiveness as an intranasal treatment aimed at achieving rapid seizure control.
North America acute repetitive seizures market dominated the global market with a revenue share of 43.0% in 2024. Market growth in the region is driven by a high prevalence of epilepsy and neurological disorders, complemented by a robust healthcare infrastructure.
The acute repetitive seizures market in Japan dominated the Asia Pacific acute repetitive seizures market in 2024. The aging population, coupled with rising awareness of neurological disorders, stimulates demand for effective therapies.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Acute Repetitive Seizures Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

Chapter 4. Acute Repetitive Seizures Market: Product Business Analysis

4.1. Product Market Share, 2024 & 2030
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. USL-261
- 4.4.1. USL-261 Market, 2018 - 2030 (USD Million)
4.5. NRL-1
- 4.5.1. NRL-1 Market, 2018 - 2030 (USD Million)
4.6. AZ-002
- 4.6.1. AZ-002 Market, 2018 - 2030 (USD Million)
4.7. Diastat Rectal Gel
- 4.7.1. Diastat Rectal Gel Market, 2018 - 2030 (USD Million)
4.8. Others
- 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Acute Repetitive Seizures Market: Regional Estimates & Trend Analysis

5.1. Regional Market Share Analysis, 2024 & 2030
5.2. Regional Market Dashboard
5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
5.4. North America
- 5.4.1. North America Acute Repetitive Seizures Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 5.4.2. U.S.
  - 5.4.2.1. Key Country Dynamics
  - 5.4.2.2. Regulatory Framework
  - 5.4.2.3. Competitive Insights
  - 5.4.2.4. U.S. Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.4.3. Canada
  - 5.4.3.1. Key Country Dynamics
  - 5.4.3.2. Regulatory Framework
  - 5.4.3.3. Competitive Insights
  - 5.4.3.4. Canada Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.4.4. Mexico
  - 5.4.4.1. Key Country Dynamics
  - 5.4.4.2. Regulatory Framework
  - 5.4.4.3. Competitive Insights
  - 5.4.4.4. Mexico Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5. Europe
- 5.5.1. Europe Acute Repetitive Seizures Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 5.5.2. UK
  - 5.5.2.1. Key Country Dynamics
  - 5.5.2.2. Regulatory Framework
  - 5.5.2.3. Competitive Insights
  - 5.5.2.4. UK Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.5.3. Germany
  - 5.5.3.1. Key Country Dynamics
  - 5.5.3.2. Regulatory Framework
  - 5.5.3.3. Competitive Insights
  - 5.5.3.4. Germany Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.5.4. France
  - 5.5.4.1. Key Country Dynamics
  - 5.5.4.2. Regulatory Framework
  - 5.5.4.3. Competitive Insights
  - 5.5.4.4. France Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.5.5. Italy
  - 5.5.5.1. Key Country Dynamics
  - 5.5.5.2. Regulatory Framework
  - 5.5.5.3. Competitive Insights
  - 5.5.5.4. Italy Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.5.6. Spain
  - 5.5.6.1. Key Country Dynamics
  - 5.5.6.2. Regulatory Framework
  - 5.5.6.3. Competitive Insights
  - 5.5.6.4. Spain Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.5.7. Norway
  - 5.5.7.1. Key Country Dynamics
  - 5.5.7.2. Regulatory Framework
  - 5.5.7.3. Competitive Insights
  - 5.5.7.4. Norway Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.5.8. Denmark
  - 5.5.8.1. Key Country Dynamics
  - 5.5.8.2. Regulatory Framework
  - 5.5.8.3. Competitive Insights
  - 5.5.8.4. Denmark Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.5.9. Sweden
  - 5.5.9.1. Key Country Dynamics
  - 5.5.9.2. Regulatory Framework
  - 5.5.9.3. Competitive Insights
  - 5.5.9.4. Sweden Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6. Asia Pacific
- 5.6.1. Asia Pacific Acute Repetitive Seizures Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 5.6.2. Japan
  - 5.6.2.1. Key Country Dynamics
  - 5.6.2.2. Regulatory Framework
  - 5.6.2.3. Competitive Insights
  - 5.6.2.4. Japan Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.6.3. China
  - 5.6.3.1. Key Country Dynamics
  - 5.6.3.2. Regulatory Framework
  - 5.6.3.3. Competitive Insights
  - 5.6.3.4. China Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.6.4. India
  - 5.6.4.1. Key Country Dynamics
  - 5.6.4.2. Regulatory Framework
  - 5.6.4.3. Competitive Insights
  - 5.6.4.4. India Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.6.5. South Korea
  - 5.6.5.1. Key Country Dynamics
  - 5.6.5.2. Regulatory Framework
  - 5.6.5.3. Competitive Insights
  - 5.6.5.4. South Korea Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.6.6. Australia
  - 5.6.6.1. Key Country Dynamics
  - 5.6.6.2. Regulatory Framework
  - 5.6.6.3. Competitive Insights
  - 5.6.6.4. Australia Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.6.7. Thailand
  - 5.6.7.1. Key Country Dynamics
  - 5.6.7.2. Regulatory Framework
  - 5.6.7.3. Competitive Insights
  - 5.6.7.4. Thailand Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.7. Latin America
- 5.7.1. Latin America Acute Repetitive Seizures Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 5.7.2. Brazil
  - 5.7.2.1. Key Country Dynamics
  - 5.7.2.2. Regulatory Framework
  - 5.7.2.3. Competitive Insights
  - 5.7.2.4. Brazil Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.7.3. Argentina
  - 5.7.3.1. Key Country Dynamics
  - 5.7.3.2. Regulatory Framework
  - 5.7.3.3. Competitive Insights
  - 5.7.3.4. Argentina Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.8. MEA
- 5.8.1. MEA Acute Repetitive Seizures Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 5.8.2. South Africa
  - 5.8.2.1. Key Country Dynamics
  - 5.8.2.2. Regulatory Framework
  - 5.8.2.3. Competitive Insights
  - 5.8.2.4. South Africa Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.8.3. Saudi Arabia
  - 5.8.3.1. Key Country Dynamics
  - 5.8.3.2. Regulatory Framework
  - 5.8.3.3. Competitive Insights
  - 5.8.3.4. Saudi Arabia Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.8.4. UAE
  - 5.8.4.1. Key Country Dynamics
  - 5.8.4.2. Regulatory Framework
  - 5.8.4.3. Competitive Insights
  - 5.8.4.4. UAE Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.8.5. Kuwait
  - 5.8.5.1. Key Country Dynamics
  - 5.8.5.2. Regulatory Framework
  - 5.8.5.3. Competitive Insights
  - 5.8.5.4. Kuwait Acute Repetitive Seizures Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

6.1. Participant Overview
6.2. Company Market Position Analysis
6.3. Company Categorization
6.4. Strategy Mapping
6.5. Company Profiles/Listing
- 6.5.1. UCB S.A., Belgium
  - 6.5.1.1. Overview
  - 6.5.1.2. Financial Performance
  - 6.5.1.3. Product Benchmarking
  - 6.5.1.4. Strategic Initiatives
- 6.5.2. Neurelis, Inc.
  - 6.5.2.1. Overview
  - 6.5.2.2. Financial Performance
  - 6.5.2.3. Product Benchmarking
  - 6.5.2.4. Strategic Initiatives
- 6.5.3. Bausch Health Companies Inc.
  - 6.5.3.1. Overview
  - 6.5.3.2. Financial Performance
  - 6.5.3.3. Product Benchmarking
  - 6.5.3.4. Strategic Initiatives
- 6.5.4. Grupo Ferrer Internacional, S.A.
  - 6.5.4.1. Overview
  - 6.5.4.2. Financial Performance
  - 6.5.4.3. Product Benchmarking
  - 6.5.4.4. Strategic Initiatives
- 6.5.5. SERB
  - 6.5.5.1. Overview
  - 6.5.5.2. Financial Performance
  - 6.5.5.3. Product Benchmarking
  - 6.5.5.4. Strategic Initiatives

급성 반복 발작 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별, 부문 예측(2025-2030년)

Acute Repetitive Seizures Market Size, Share & Trends Analysis Report By Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) And Segment Forecasts, 2025 - 2030

급성 반복 발작 시장의 성장과 동향

급성 반복 발작 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 급성 반복 발작 시장의 변수, 동향, 범위

제4장 급성 반복 발작 시장 : 제품 비즈니스 분석

제5장 급성 반복 발작 시장 : 지역별, 추정 및 동향 분석